Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Platelet activation is a key factor in thrombosis and may impede the effectiveness of thrombolytic therapy.
• Tissue-type plasminogen activator (t-PA) is a critical treatment for acute myocardial infarction, but its efficacy can be influenced by platelet response.

Purpose of the Study:

• To investigate platelet activation during coronary thrombolysis with intravenous t-PA in patients experiencing acute myocardial infarction.
• To assess thromboxane A2 and prostacyclin (PGI2) biosynthesis as markers of platelet activation and reperfusion.

Main Methods:

• Measurement of urinary 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-PGF1 alpha excretion in patients undergoing t-PA treatment.
• Comparison of metabolite levels in patients pretreated with aspirin versus those without aspirin.
• Analysis of metabolite levels in relation to reperfusion status.

Main Results:

• Intravenous t-PA administration significantly increased thromboxane A2 biosynthesis, indicated by elevated urinary 2,3-dinor-thromboxane B2 levels for 48 hours.
• Aspirin pretreatment abolished the t-PA-induced increase in thromboxane A2 biosynthesis.
• Prostacyclin (PGI2) biosynthesis also increased post-t-PA, but this increase was significantly lower in patients who achieved reperfusion compared to those who did not.

Conclusions:

• These findings provide evidence for significant platelet activation during t-PA-mediated coronary thrombolysis.
• The reduction in PGI2 biosynthesis in successfully reperfused patients may serve as a marker for vascular reperfusion injury.
• Amplified platelet activation could be a consequence of reperfusion injury, potentially impacting therapeutic outcomes.